The US Food and Drug Administration (FDA) is investigating unpublished data suggesting that incretin mimetics used to treat type 2 diabetes may increase the risk of pancreatitis or precancerous changes in the pancreas (http://tinyurl.com/437wln9).
According to the FDA, a team of academic researchers examined pancreatic tissue samples from patients who died of unspecified causes. The data prompted the agency to begin its own investigation of potential pancreatic toxicity associated with this class of drugs, which includes exenatide, liraglutide, sitagliptin, saxagliptin, alogliptin, and linagliptin. The agency emphasized that it has not yet reached a conclusion.
Kuehn BM. Diabetes Drugs Investigated. JAMA. 2013;309(16):1674. doi:10.1001/jama.2013.4243